Ipramol Steri-Neb

Ipratropium bromide and Salbutamol, the active ingredients in Ipramol Steri‑Neb, are bronchodilators presented as a nebulizer solution for inhalation use. They relieve bronchospasm in patients with asthma, chronic obstructive pulmonary disease (COPD) and acute bronchospasm.

GNH USA supplies Ipramol Steri‑Neb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipramol Steri‑Neb acts on the respiratory airways to provide bronchodilation in obstructive lung diseases.

Asthma: improves airflow and reduces wheezing during acute episodes. COPD: eases chronic bronchoconstriction and enhances exercise tolerance. Acute bronchospasm: rapidly reverses sudden airway narrowing in emergency settings.

Adverse reactions may occur with inhalation of the nebulizer solution.

Common Side Effects: - Dry mouth - Cough or throat irritation - Tremor - Headache - Palpitations - Nausea

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe tachycardia or arrhythmia - Angioedema - Hypotension - Acute respiratory distress - Anaphylactic reaction

Use Ipramol Steri‑Neb with careful clinical assessment and monitoring.

Assess cardiac status: patients with arrhythmias may need closer observation. Monitor for paradoxical bronchospasm: discontinue if symptoms worsen. Use cautiously in urinary retention or narrow‑angle glaucoma. Avoid in known hypersensitivity to ipratropium, salbutamol, or formulation excipients. Store at room temperature: keep in the original container, protect from light and moisture.

Ipramol Steri‑Neb may interact with other medications that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid): - Non‑selective β‑blockers: can diminish bronchodilator effect. - High‑dose β‑agonist combinations: increase risk of tachycardia and arrhythmia. - Anticholinergic agents: may enhance anticholinergic side effects.

Moderate Interactions (Monitor Closely): - Theophylline: additive stimulant effect on the heart. - Diuretics causing hypokalemia: may potentiate salbutamol‑induced cardiac effects. - ACE inhibitors: monitor for cough or bronchospasm exacerbation.